Allergenic Product Reclassification Will Be Discussed At April 7 Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The committee will assess whether Class IIIA products should remain licensed or be pulled from the market. An update on FDA's "critical path" drug development initiative is also on the agenda.